
-
Zuckerberg denies Meta bought rivals to conquer them
-
Starc stars as Delhi beat Rajasthan in Super Over
-
Weinstein asks to sleep in hospital, citing prison 'mistreatment'
-
Amorim asks McIlroy to bring Masters magic to Man Utd
-
Ruud keeps Barcelona Open defence on course
-
Trump tariffs could put US Fed in a bind, Powell warns
-
CONCACAF chief rejects 64-team World Cup plan for 2030
-
Putin praises Musk, compares him to Soviet space hero
-
Son to miss Spurs' Europa League trip to Frankfurt
-
Trump tariffs could put the US Fed in a bind, Powell warns
-
US judge says 'probable cause' to hold Trump admin in contempt
-
India opposition slams graft charges against Gandhis
-
Nate Bargatze to host Emmys: organizers
-
US Fed Chair warns of 'tension' between employment, inflation goals
-
Trump touts trade talks, China calls out tariff 'blackmail'
-
US judge says 'probable cause' to hold govt in contempt over deportations
-
US eliminates unit countering foreign disinformation
-
Germany sees 'worrying' record dry spell in early 2025
-
Israel says 30 percent of Gaza turned into buffer zone
-
TikTok tests letting users add informative 'Footnotes'
-
Global uncertainty will 'certainly' hit growth: World Bank president
-
EU lists seven 'safe' countries of origin, tightening asylum rules
-
Chelsea fans must 'trust' the process despite blip, says Maresca
-
Rebel rival government in Sudan 'not the answer': UK
-
Prague zoo breeds near-extinct Brazilian mergansers
-
Macron to meet Rubio, Witkoff amid transatlantic tensions
-
WTO chief says 'very concerned' as tariffs cut into global trade
-
Sports bodies have 'no excuses' on trans rules after court ruling: campaigners
-
Zverev joins Shelton in Munich ATP quarters
-
The Trump adviser who wants to rewrite the global financial system
-
US senator travels to El Salvador over wrongly deported migrant
-
UN watchdog chief says Iran 'not far' from nuclear bomb
-
Trump says 'joke' Harvard should be stripped of funds
-
Canada central bank holds interest rate steady amid tariffs chaos
-
Rubio headed to Paris for Ukraine war talks
-
Australian PM vows not to bow to Trump on national interest
-
New attacks target France prison guard cars, home
-
Global trade uncertainty could have 'severe negative consequences': WTO chief
-
Google facing £5 bn UK lawsuit over ad searches: firms
-
Onana to return in goal for Man Utd against Lyon: Amorim
-
Tiktok bans user behind Gisele Pelicot 'starter kit' meme
-
'Put it on': Dutch drive for bike helmets
-
China's Xi meets Malaysian leaders, vows to 'safeguard' Asia allies
-
France urges release of jailed Russian journalists who covered Navalny
-
Gabon striker Boupendza dies after 11th floor fall
-
UK top court rules definition of 'woman' based on sex at birth
-
PSG keep Champions League bid alive, despite old ghosts reappearing
-
Stocks retreat as US hits Nvidia chip export to China
-
China's Xi meets Malaysian leaders in diplomatic charm offensive
-
Israel says no humanitarian aid will enter Gaza

UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
V.F.Barreira--PC